Advanced Search

Home > Journals > International Angiology > Past Issues > International Angiology 2011 August;30(4) > International Angiology 2011 August;30(4):299-320



A Journal on Angiology

Official Journal of the International Union of Angiology, the International Union of Phlebology and the Central European Vascular Forum
Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,899

Frequency: Bi-Monthly

ISSN 0392-9590

Online ISSN 1827-1839


International Angiology 2011 August;30(4):299-320


Anticoagulant drugs: what is new?

Kei A. 1, Florentin M. 1,2, Elisaf M. S. 1, Liberopoulos E. N. 1

1 Department of Internal Medicine, University of Ioannina Medical School, Ioannina, Greece
2 Department of Clinical Biochemistry (Vascular Prevention Clinics), Royal Free campus,
University College London Medical School, University College London (UCL), London UK

Heparins and vitamin K antagonists have been the cornerstones of anticoagulation treatment for several decades. Despite their effectiveness, these agents have limitations which can include food and drug interactions and the need for monitoring. It follows that there is a need for new anticoagulants. There are numerous promising agents at various stages of evaluation. Those in the most advanced stages of development are the oral factor Xa and the thrombin inhibitors, which are the focus of this review.

language: English


top of page